Pirae

Researchers are evaluating the impact of liquid biopsy technology to improve treatment for patients with metastatic cancer receiving care in community hospitals. This prospective biomarker study aims to demonstrate how analyzing circulating tumor DNA ctDNA using a large gene panel and microsatellite instability testing can help guide personalized therapy decisions. The study includes patients with various metastatic solid tumors, including castration-resistant prostate cancer and certain types of metastatic breast cancer resistant to standard therapies. Participants will have a blood sample taken at the start of their first-line treatment, which may include chemotherapy, immunotherapy, endocrine therapy, or targeted therapy. The collected plasma samples will undergo Next Generation Sequencing NGS to detect gene alterations and MSI status. Results will be reviewed by a Molecular Tumor Board MTB that includes specialists from multiple centers to discuss treatment options based on the molecular profile. During the study, researchers will monitor the proportion of patients with successful ctDNA sequencing and how often molecular profiling information guides treatment. They will also evaluate response rates, survival outcomes, and the timing between liquid biopsy and therapy initiation over a follow-up period of 72 months. Patients will be assessed for measurable disease, performance status, and compliance with study procedures, including providing informed consent. The study carefully tracks safety and effectiveness of molecular-guided therapy in a community oncology setting.

Researchers are investigating the genetic and molecular factors involved in gout, inflammation, and metabolic diseases in French Polynesia. This study aims to better understand the high rates of gout and hyperuricaemia in the adult population, as well as related conditions like obesity and type 2 diabetes. The goal is to identify genetic contributors and track the long-term effects of hyperuricaemia and associated health risks. Participants are grouped into the general population, gout patients, and a follow-up group from a previous 2021 study called TOPATA. The study involves collecting sociodemographic data, clinical exams, questionnaires, and blood and urine samples for genetic and biochemical analyses. Some gout patients with recent attacks will provide additional samples one week later to monitor acute flare changes. During the study, participants will undergo various assessments including physical exams, laboratory tests, and questionnaires about health, diet, and lifestyle. Researchers will measure genetic associations, correlations between gout and metabolic conditions, disease progression, and cardiovascular events. The study spans several years, with key outcomes assessed at 12 months and up to 4 years, to better understand disease mechanisms and support future therapies.

Researchers are studying skin reactions related to thoracic implantable catheter chamber ICC dressings in patients newly treated with systemic chemotherapy. The ICC is widely used in oncology to administer treatments without damaging veins, but it may cause complications such as infections and skin reactions including redness, itching, and dermabrasion. This study aims to confirm the frequency of these skin reactions in a large group and explore factors like patient characteristics, treatment side effects, dressing application, duration, and climate conditions that might affect skin tolerance. The study will follow a group of 500 patients receiving first-line chemotherapy using a thoracic implantable catheter chamber. Data will be collected to observe the incidence and risk factors for skin reactions linked to the dressings. The research will also evaluate the consequences of these reactions on treatment management, infection risk, and patient comfort. The study includes patients from multiple centers, including a site in the French West Indies, to examine differences across skin types and environmental conditions. Participants will be monitored over an average of 18 months to measure the occurrence of skin reactions and their impact on therapy and quality of life. The study involves regular assessments to identify risk factors and track any treatment changes or complications such as catheter infections. Researchers will also assess patient comfort and satisfaction related to skin reactions. This observational research complements existing studies on catheter infections and aims to improve care practices for patients using ICC dressings.